• ArcScan

  Led · Series B · Jul 2021

  ArcScan develops the Insight® 100, a very‑high‑frequency (50 MHz) ultrasound imaging system that produces micron‑level, high‑resolution images of the entire anterior segment, including areas behind the iris. The system uses Swept Beam Liquid Interface™ technology and a mechanically controlled transducer to scan the eye in an arc motion, and the platform includes the device, Insight software, a fluidics module, electronics unit, and EyeSeal disposables. ArcScan's technology was originally developed and patented at Columbia/Weill University and is positioned to provide accurate biometry for pre‑ and post‑operative IOL, premium IOL, and ICL cases. The company emphasizes improved clinical outcomes by enabling accurate lens position, tilt, and volume measurements to reduce lens exchanges. ArcScan intends to leverage strategic partnerships to expand its market presence, particularly in large ophthalmology markets. The company is headquartered in Golden, Colorado.

• Eirion Therapeutics

  Led · Series A · Mar 2021

  Eirion Therapeutics is a clinical-stage biopharmaceutical company based in Woburn, Mass., developing next-generation prescription products for aesthetic dermatology. Its pipeline focuses on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. The company is led by Jon Edelson, MD, who serves as Chairman, CEO, and President. Eirion plans to pursue additional indications that address other major unmet clinical needs for physicians and their patients. Financially, the company had previously raised approximately $11M via convertible notes, which will convert into Series A Preferred Stock in connection with the new financing. The recent Series A and licensing agreement with Haohai is structured to support development and commercialization efforts.

• Recros Medica

  Led · Series A · Nov 2019

  Recros Medica develops the Nuvellus® Focal Contouring system to reduce skin laxity and improve focal contouring. The Nuvellus® platform is based on proprietary rotational fractional resection technology and may offer a novel procedure that produces results from a single treatment. The company is also developing Nuvellus® to facilitate autologous dermal transfer as a natural alternative to commercial dermal fillers. Nearly 100 subjects have been treated across four IRB-approved clinical trials, and Recros is planning a pivotal clinical study. Recros is led by president and CEO Tom Albright. The company closed a $14M Series A to continue Nuvellus® development, conduct the pivotal study and pursue FDA clearance to commercialize in the U.S. Recros Medica, co-founded in 2014, is developing a medical aesthetic technology platform called Rotational Fractional Resection with multiple clinical applications. The company is led by President and CEO Tom Albright and was co-founded by Dr. Edward Knowlton and David F. Hale. The platform targets treatment of skin laxity and focal aesthetic contour deformities in the submentum, upper arms, knees and other areas where visible scarring limits traditional plastic surgery. Recros is a development-stage company based in San Diego, CA. It closed a $9M financing to expand its technology platforms in the aesthetics market. The company also strengthened its board with the additions of Christoph Westphal of Longwood Fund and Mark Kerslake of the Province Group.

No current team members are available.